Patterns of TNF switching and time to switch 2003–2005.
| Initial Drug | N (total) | Median Days on Initial Drug (75th–25th %), Total Cohort | First Switch | N (%) | Median Days to First Switch (75th–25th %) |
|---|---|---|---|---|---|
| Etanercept | 2404 | 347.5 (578–158.5) | No Switch | 2103 (87.48) | 388 (606–187) |
| Adalimumab | 194 (8.07) | 151.5 (280–70) | |||
| Infliximab | 107 (4.45) | 127 (291–64) | |||
| Adalimumab | 963 | 365 (569–143) | No Switch | 818 (84.94) | 412 (607–184) |
| Etanercept | 110 (11.42) | 114 (232–55) | |||
| Infliximab | 35 (3.63) | 141 (243–70) | |||
| Infliximab | 1253 | 464 (693–210) | No Switch | 1128 (90.02) | 504.5 (718–231) |
| Etanercept | 54 (4.31) | 145 (307–74) | |||
| Adalimumab | 71 (5.67) | 185 (330–88) |